ZA201800558B - Combination therapy using acamprosate and d-cycloserine - Google Patents
Combination therapy using acamprosate and d-cycloserineInfo
- Publication number
- ZA201800558B ZA201800558B ZA201800558A ZA201800558A ZA201800558B ZA 201800558 B ZA201800558 B ZA 201800558B ZA 201800558 A ZA201800558 A ZA 201800558A ZA 201800558 A ZA201800558 A ZA 201800558A ZA 201800558 B ZA201800558 B ZA 201800558B
- Authority
- ZA
- South Africa
- Prior art keywords
- acamprosate
- cycloserine
- combination therapy
- therapy
- combination
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562200864P | 2015-08-04 | 2015-08-04 | |
| PCT/US2016/045547 WO2017024129A1 (en) | 2015-08-04 | 2016-08-04 | Combination therapy using acamprosate and d-cycloserine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201800558B true ZA201800558B (en) | 2019-10-30 |
Family
ID=57944041
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA201800558A ZA201800558B (en) | 2015-08-04 | 2018-01-26 | Combination therapy using acamprosate and d-cycloserine |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20180221315A1 (enExample) |
| EP (1) | EP3331518A4 (enExample) |
| JP (2) | JP2018526345A (enExample) |
| KR (1) | KR20180034442A (enExample) |
| AU (2) | AU2016303610A1 (enExample) |
| CA (1) | CA2993614A1 (enExample) |
| HK (1) | HK1255584A1 (enExample) |
| IL (1) | IL257035A (enExample) |
| SG (1) | SG10201914045QA (enExample) |
| WO (1) | WO2017024129A1 (enExample) |
| ZA (1) | ZA201800558B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017024129A1 (en) * | 2015-08-04 | 2017-02-09 | Confluence Pharmaceuticals, Llc | Combination therapy using acamprosate and d-cycloserine |
| IL270654B2 (en) | 2017-05-17 | 2024-07-01 | Confluence Pharmaceuticals Llc | Formulations of homotaurines and salts thereof |
| CN110996946A (zh) | 2017-05-25 | 2020-04-10 | 格莱泰施有限责任公司 | 用于治疗创伤后应激障碍的制剂 |
| US11291654B2 (en) * | 2018-09-13 | 2022-04-05 | Syneurx International (Taiwan) Corp. | Formulations of cycloserine compounds and applications thereof |
| JP2025069475A (ja) * | 2022-03-08 | 2025-05-01 | ソシウム株式会社 | Ｔｄｐ－４３の凝集の抑制剤、ｔｄｐ－４３が過剰発現している細胞の細胞死の抑制剤、及びｔｄｐ－４３の凝集を伴う疾患の治療又は予防剤 |
| CN119212703A (zh) * | 2023-04-27 | 2024-12-27 | 寿协株式会社 | 肌萎缩性侧索硬化症的治疗剂或预防剂 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1073432T1 (de) * | 1998-04-14 | 2002-02-07 | The General Hospital Corp., Boston | Verwendung von glycinrezeptoragonisten und glycinaufnahmeinhibitoren zur behandlung neuropsychiatrischer beschwerden |
| US20100216734A1 (en) * | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| JP2010532331A (ja) * | 2007-07-05 | 2010-10-07 | アンセルム（アンスチチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル） | 抗痙攣医薬組成物 |
| DK2395990T3 (en) * | 2009-02-12 | 2015-02-23 | Univ Indiana Res & Tech Corp | Material and methods for the treatment of developmental disorders comprising co-morbid and idiopathic autism |
| WO2010099217A1 (en) * | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| KR20130002292A (ko) * | 2011-06-28 | 2013-01-07 | 주식회사 비보존 | 다중 타겟팅의 상승 효과를 유발하는 유효물질의 조합 및 그 용도 |
| US10709668B2 (en) * | 2015-05-04 | 2020-07-14 | Confluence Pharmaceuticals, Llc | Sprinkle formulations of acamprosate |
| WO2017024129A1 (en) * | 2015-08-04 | 2017-02-09 | Confluence Pharmaceuticals, Llc | Combination therapy using acamprosate and d-cycloserine |
-
2016
- 2016-08-04 WO PCT/US2016/045547 patent/WO2017024129A1/en not_active Ceased
- 2016-08-04 SG SG10201914045QA patent/SG10201914045QA/en unknown
- 2016-08-04 AU AU2016303610A patent/AU2016303610A1/en not_active Abandoned
- 2016-08-04 HK HK18114711.9A patent/HK1255584A1/zh unknown
- 2016-08-04 KR KR1020187002542A patent/KR20180034442A/ko not_active Ceased
- 2016-08-04 CA CA2993614A patent/CA2993614A1/en not_active Abandoned
- 2016-08-04 EP EP16833870.5A patent/EP3331518A4/en not_active Withdrawn
- 2016-08-04 US US15/749,705 patent/US20180221315A1/en not_active Abandoned
- 2016-08-04 JP JP2018504281A patent/JP2018526345A/ja active Pending
-
2018
- 2018-01-21 IL IL257035A patent/IL257035A/en unknown
- 2018-01-26 ZA ZA201800558A patent/ZA201800558B/en unknown
-
2020
- 2020-06-02 US US16/890,533 patent/US20200360316A1/en not_active Abandoned
-
2021
- 2021-06-22 JP JP2021103459A patent/JP2021152060A/ja active Pending
-
2022
- 2022-04-01 AU AU2022202218A patent/AU2022202218A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| HK1255584A1 (zh) | 2019-08-23 |
| JP2018526345A (ja) | 2018-09-13 |
| KR20180034442A (ko) | 2018-04-04 |
| EP3331518A1 (en) | 2018-06-13 |
| US20180221315A1 (en) | 2018-08-09 |
| US20200360316A1 (en) | 2020-11-19 |
| SG10201914045QA (en) | 2020-03-30 |
| IL257035A (en) | 2018-03-29 |
| EP3331518A4 (en) | 2019-04-03 |
| WO2017024129A1 (en) | 2017-02-09 |
| JP2021152060A (ja) | 2021-09-30 |
| AU2016303610A1 (en) | 2018-02-01 |
| AU2022202218A1 (en) | 2022-04-21 |
| CA2993614A1 (en) | 2017-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL263521A (en) | Combination therapy | |
| SG11201802794PA (en) | Therapeutic compounds and methods | |
| GB201707153D0 (en) | Therapy | |
| GB201516442D0 (en) | Combination therapy | |
| IL265406B (en) | combined treatment | |
| IL257976A (en) | Combined treatment | |
| GB201708663D0 (en) | Therapy | |
| ZA201800558B (en) | Combination therapy using acamprosate and d-cycloserine | |
| ZA201804155B (en) | Combination therapy | |
| GB201609597D0 (en) | Therapy | |
| GB201604318D0 (en) | Combination therapy | |
| GB201604316D0 (en) | Combination therapy | |
| GB201603653D0 (en) | Combination Therapy | |
| IL265340A (en) | Combination therapy | |
| GB201617470D0 (en) | Novel therapy | |
| GB201609735D0 (en) | Combination therapy | |
| GB201618477D0 (en) | Therapy | |
| GB201615923D0 (en) | Macrophage-based therapy | |
| GB201707945D0 (en) | Cnacer therapy | |
| GB201707183D0 (en) | Macrophage-based therapy | |
| GB201609721D0 (en) | Cobination therapy | |
| GB201609322D0 (en) | Therapy | |
| GB201609312D0 (en) | Therapy | |
| GB201703453D0 (en) | Therapy | |
| GB201703070D0 (en) | Therapy |